Table 2 |
|||
|
Treatment outcomes at D14 |
|||
| Treatment outcome (No, %) [95 CI] |
|||
|
|
|||
| Rural area (n = 62) |
Urban area (n = 55) |
Total (n = 117) |
|
|
|
|||
| ETF |
0 (0%) [0–6%] |
0 (0%) [0–6%] |
0 (0%) [0–3%] |
| LCF |
|||
| - Recrudescence |
0 (0%) [0–6%] |
5 (9%) [3–20%] |
5 (4%) [1–10%] |
| - New infection |
0 (0%) [0–6%] |
1 (2%) [0–10%] |
1 (1%) [0–5%] |
| - No genotyping results |
1 (2%) [0–9%] |
0 (0%) [0–6%] |
1 (1%) [0–5%] |
| LPF |
|||
| - Recrudescence |
1 (2%) [0–9%] |
1 (2%) [0–10%] |
2 (2%) [0–6%] |
| - New infection |
2 (3%) [0–11%] |
2 (4%) [0–13%] |
4 (3%) [1–9%] |
| - No genotyping results |
1 (2%) [0–9%] |
0 (0%) [0–6%] |
1 (1%) [0–5%] |
| ACPR |
57 (92%) [82–97%] |
46 (84%) [71–92%] |
103 (88%) [81–93%] |
| ACPR (pcr-corrected) |
58 (94%) [84–98%] |
50 (91%) [80–97%] |
108 (92%) [86–96%] |
|
|
|||
|
Mandi et al. Malaria Journal 2008 7:58 doi:10.1186/1475-2875-7-58 |
|||
